I agree that this site is using cookies. You can find further informations here.
X
Richmond, Gary J
155  results:
Search for persons X
?
1

Efficacy and safety of the novel capsid inhibitor lenacapav..:

Ogbuagu, Onyema ; Segal-Maurer, Sorana ; Ratanasuwan, Winai...
The Lancet HIV.  10 (2023)  8 - p. e497-e505 , 2023
Link: https://doi.org/10.1016/..
 
?
2

1596. Efficacy and Safety of Long-Acting Subcutaneous Lenac..:

Ogbuagu, Onyema ; DeJesus, Edwin ; Berhe, Mezgebe...
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
3

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Mont..:

Overton, Edgar T ; Richmond, Gary ; Rizzardini, Giuliano...
Clinical Infectious Diseases.  76 (2023)  9 - p. 1646-1654 , 2023
Link: https://doi.org/10.1093/..
 
?
4

Long-acting cabotegravir and rilpivirine for HIV-1 suppress..:

Mills, Anthony ; Richmond, Gary J. ; Newman, Cheryl...
AIDS.  36 (2021)  2 - p. 195-203 , 2021
Link: https://doi.org/10.1097/..
 
?
5

Efficacy, Safety, and Durability of Long-Acting Cabotegravi..:

Smith, Graham H R ; Henry, W Keith ; Podzamczer, Daniel...
Open Forum Infectious Diseases.  8 (2021)  9 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
6

116. Antiviral Activity and Safety of Long-acting Cabotegra..:

Mills, Anthony ; Richmond, Gary J ; Newman, Cheryl...
Open Forum Infectious Diseases.  7 (2020)  Supplement_1 - p. S186-S187 , 2020
Link: https://doi.org/10.1093/..
 
?
7

Long-acting cabotegravir and rilpivirine dosed every 2 mont..:

Overton, Edgar T ; Richmond, Gary ; Rizzardini, Giuliano...
The Lancet.  396 (2020)  10267 - p. 1994-2005 , 2020
Link: https://doi.org/10.1016/..
 
?
8

Intraspecific variation in thermal acclimation and toleranc..:

Tonione, Maria Adelena ; Cho, So Mi ; Richmond, Gary..
Ecology and Evolution.  10 (2020)  11 - p. 4749-4761 , 2020
Link: https://doi.org/10.1002/..
 
?
9

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV M..:

Rizzardini, Giuliano ; Overton, Edgar T. ; Orkin, Chloe...
JAIDS Journal of Acquired Immune Deficiency Syndromes.  85 (2020)  4 - p. 498-506 , 2020
Link: https://doi.org/10.1097/..
 
?
10

Experiences with long acting injectable ART: A qualitative ..:

Kerrigan, Deanna ; Mantsios, Andrea ; Gorgolas, Miguel...
PLOS ONE.  13 (2018)  1 - p. e0190487 , 2018
Link: https://doi.org/10.1371/..
 
?
11

Forty-eight-Week Safety and Efficacy On-Treatment Analysis ..:

Emu, Brinda ; Fessel, W Jeffery ; Schrader, Shannon...
Open Forum Infectious Diseases.  4 (2017)  suppl_1 - p. S38-S39 , 2017
Link: https://doi.org/10.1093/..
 
?
12

Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age,..:

Walmsley, Sharon ; Richmond, Gary ; Bredeek, Fritz...
Open Forum Infectious Diseases.  4 (2017)  suppl_1 - p. S427-S427 , 2017
Link: https://doi.org/10.1093/..
 
?
13

Primary Efficacy Endpoint and Safety Results of Ibalizumab ..:

Lalezari, Jacob ; Fessel, W. Jeffery ; Schrader, Shannon...
Open Forum Infectious Diseases.  3 (2016)  suppl_1 - p. , 2016
Link: https://doi.org/10.1093/..
 
?
14

Joseph Ransdell and the Communicational Process of Philosop..:

Richmond, Gary ; Udell, Ben
Transactions of the Charles S. Peirce Society: A Quarterly Journal in American Philosophy.  49 (2013)  4 - p. 457-466 , 2013
Link: https://www.jstor.org/st..
 
?
15

Safety and Efficacy of Dolutegravir in Treatment-Experience..:

Eron, Joseph J. ; Clotet, Bonaventura ; Durant, Jacques...
The Journal of Infectious Diseases.  207 (2013)  5 - p. 740-748 , 2013
Link: http://dx.doi.org/10.109..
 
1-15